NCT06997042 Creation of Arteriovenous Fistulas for Hemodialysis Using the End-to-side Anastomotic Technique vs. Piggyback.
| NCT ID | NCT06997042 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Clinic of Barcelona |
| Condition | Chronic Kidney Disease Requiring Hemodialysis |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2027-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 130 participants in total. It began in 2025-05-01 with a primary completion date of 2027-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is designed to compare two surgical techniques used to create arteriovenous fistulas (AVFs), which are necessary for hemodialysis in patients with advanced chronic kidney disease (CKD). AVFs are preferred over other forms of vascular access because they last longer and have fewer complications. However, many AVFs fail to mature properly, making them unusable for dialysis. The two techniques being studied are the traditional End-to-Side (ETS) method and a newer technique called Piggyback Straight Line Onlay Technique (pSLOT). Early studies suggest that pSLOT may reduce complications like narrowing (stenosis), clotting (thrombosis), and failure of the AVF, but more robust data from randomized clinical trials is needed. Patients aged 18 or older with stage 4 or 5 CKD, who are eligible for a new AVF and meet health criteria, may participate. During the operation, participants are randomly assigned to receive either the ETS or pSLOT technique. The procedure is done under local or regional anesthesia. Follow-up appointments are scheduled at 1 and 12 months to assess fistula maturation, blood flow, and whether it can be successfully used for dialysis. Remote follow-ups are allowed if needed. Participation is voluntary, requires informed consent, and all data is kept strictly confidential. The study follows national and international ethical standards and has been approved by an ethics committee.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * Able to meet protocol requirements, including follow-up. * Incident or prevalent patient with advanced chronic kidney disease in the hemodialysis stage (stage 5D). * In predialysis patients (stage 5), if renal replacement therapy (hemodialysis) is anticipated to be required within the next 6 months (based on standard clinical criteria). * Who, based on their associated pathology and according to medical criteria, can withstand the initial surgery and arteriovenous access maintenance procedures. * Have a current ultrasound with preoperative venous and arterial mapping. * Meet the anatomical requirements for AVF creation: * Wrist: artery \>2 mm, vein \>2 mm in diameter * Elbow: artery \>3 mm, vein \>3 mm in diameter * Absence of arterial calcification or occlusion, or other aberrant arterial anatomy. * Adequate arterial and venous patency. * Vein-to-skin distance \<5 mm. * Candidate for creation of a native arteriovenous fistula for hemodialysis, either distal (radiocephalic) or proximal (humerocephalic or humerobasilic). * No immediate transplant scheduled within the next 60 days (inclusion on the kidney transplant waiting list is not a contraindication for entry into the study, nor for the creation of an arteriovenous fistula). * No prior arteriovenous surgeries in the same or proximal location. * Correct understanding of the study conditions and acceptance to participate. Exclusion Criteria: * Pregnant women. * Life expectancy \<1 year. * Arteriovenous prostheses (non-native fistulas), previous arteriovenous fistula repairs, arteriovenous accesses created in the lower extremities, and unusual (exotic) accesses. * Known or suspected central venous stenosis/occlusion on the side of the planned access. * Repair of previous arteriovenous accesses (proximal reanastomoses). * Biological immunosuppression. * History or evidence of serious systemic illness, including: * Cardiac disease (New York Heart Association functional class III or IV, as evidenced by the inability to lie still), myocardial infarction within 6 weeks prior to randomization, ventricular tachyarrhythmia requiring ongoing treatment, or unstable angina. Suspected or documented hypercoagulable or hypocoagulable state or Clinically significant active infection (White blood count \> 15,000 cells/mm3) other than the use of a treated CVC. * Any other condition that, in the investigator's judgment, prevents an adequate evaluation of the safety and efficacy of the study or poor compliance. * Patient unwilling or unable to attend follow-up follow-ups.
Contact & Investigator
Gaspar Mestres, Medicine
PRINCIPAL INVESTIGATOR
Hospital Clinic of Barcelona
Frequently Asked Questions
Who can join the NCT06997042 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Disease Requiring Hemodialysis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06997042 currently recruiting?
Yes, NCT06997042 is actively recruiting participants. Contact the research team at lopez74@clinic.cat for enrollment information.
Where is the NCT06997042 trial being conducted?
This trial is being conducted at Barcelona, Spain.
Who is sponsoring the NCT06997042 clinical trial?
NCT06997042 is sponsored by Hospital Clinic of Barcelona. The principal investigator is Gaspar Mestres, Medicine at Hospital Clinic of Barcelona. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.